SI3106149T1 - Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi - Google Patents

Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi

Info

Publication number
SI3106149T1
SI3106149T1 SI201031975T SI201031975T SI3106149T1 SI 3106149 T1 SI3106149 T1 SI 3106149T1 SI 201031975 T SI201031975 T SI 201031975T SI 201031975 T SI201031975 T SI 201031975T SI 3106149 T1 SI3106149 T1 SI 3106149T1
Authority
SI
Slovenia
Prior art keywords
long
acting
compositions
systems
receptor agonists
Prior art date
Application number
SI201031975T
Other languages
English (en)
Slovenian (sl)
Inventor
Reinhard Vehring
Michael Steven Hartman
Adrian Edward Smith
Vidya B Joshi
Sarvajna Kumar Dwivedi
Original Assignee
Pearl Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42269864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3106149(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pearl Therapeutics, Inc. filed Critical Pearl Therapeutics, Inc.
Publication of SI3106149T1 publication Critical patent/SI3106149T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1025—Respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
SI201031975T 2009-05-29 2010-05-28 Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi SI3106149T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18256509P 2009-05-29 2009-05-29
US25817209P 2009-11-04 2009-11-04
US30936510P 2010-03-01 2010-03-01
US34553610P 2010-05-17 2010-05-17
EP16164845.6A EP3106149B1 (en) 2009-05-29 2010-05-28 Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems

Publications (1)

Publication Number Publication Date
SI3106149T1 true SI3106149T1 (sl) 2020-07-31

Family

ID=42269864

Family Applications (6)

Application Number Title Priority Date Filing Date
SI201031975T SI3106149T1 (sl) 2009-05-29 2010-05-28 Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi
SI201031263A SI2435023T1 (sl) 2009-05-29 2010-05-28 Zmesi za pljučno dostavo dolgo-delujočih muskariničnih antagonistov in dolgo-delujočih agonistov beta 2 andregenskega receptorja in povezane metode in sistemi
SI201031260A SI2435024T1 (sl) 2009-05-29 2010-05-28 Zmesi za respiratorni vnos aktivnih sredstev in s tem povezane metode in sistemi
SI201031984T SI3111927T1 (sl) 2009-05-29 2010-05-28 Sestavki za respiratorni vnos aktivnih učinkovin in s tem povezani postopki in sistemi
SI201031985T SI3111926T1 (sl) 2009-05-29 2010-05-28 Sestavki, postopki in sistemi za respiratoren vnos dveh ali več aktivnih učinkovin
SI201031262A SI2435025T1 (sl) 2009-05-29 2010-05-28 Respiratorni vnos aktivnih sredstev

Family Applications After (5)

Application Number Title Priority Date Filing Date
SI201031263A SI2435023T1 (sl) 2009-05-29 2010-05-28 Zmesi za pljučno dostavo dolgo-delujočih muskariničnih antagonistov in dolgo-delujočih agonistov beta 2 andregenskega receptorja in povezane metode in sistemi
SI201031260A SI2435024T1 (sl) 2009-05-29 2010-05-28 Zmesi za respiratorni vnos aktivnih sredstev in s tem povezane metode in sistemi
SI201031984T SI3111927T1 (sl) 2009-05-29 2010-05-28 Sestavki za respiratorni vnos aktivnih učinkovin in s tem povezani postopki in sistemi
SI201031985T SI3111926T1 (sl) 2009-05-29 2010-05-28 Sestavki, postopki in sistemi za respiratoren vnos dveh ali več aktivnih učinkovin
SI201031262A SI2435025T1 (sl) 2009-05-29 2010-05-28 Respiratorni vnos aktivnih sredstev

Country Status (31)

Country Link
US (12) US20110135737A1 (enExample)
EP (6) EP2435025B1 (enExample)
JP (10) JP5823383B2 (enExample)
KR (7) KR101748892B1 (enExample)
CN (6) CN107669664B (enExample)
AR (3) AR076806A1 (enExample)
AU (3) AU2010253770B9 (enExample)
BR (3) BRPI1011229B8 (enExample)
CA (3) CA2763941A1 (enExample)
CY (8) CY1118040T1 (enExample)
DK (6) DK3111927T3 (enExample)
ES (6) ES2774367T3 (enExample)
FR (1) FR19C1040I2 (enExample)
HR (6) HRP20161098T1 (enExample)
HU (8) HUE031229T2 (enExample)
IL (3) IL216466B (enExample)
LT (8) LT2435023T (enExample)
LU (2) LUC00124I2 (enExample)
ME (1) ME03631B (enExample)
MX (5) MX393243B (enExample)
NL (1) NL300995I2 (enExample)
NO (2) NO2019026I1 (enExample)
PH (1) PH12017500778A1 (enExample)
PL (6) PL3106149T3 (enExample)
PT (6) PT3106149T (enExample)
RU (5) RU2016117972A (enExample)
SI (6) SI3106149T1 (enExample)
SM (6) SMT202000109T1 (enExample)
TW (9) TWI792140B (enExample)
WO (3) WO2010138868A2 (enExample)
ZA (4) ZA201108275B (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003220125B2 (en) 2002-03-20 2006-06-15 Mannkind Corporation Inhalation apparatus
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
EP2314298B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Microparticles comprising diketopiperazine salts for drug delivery
US10002325B2 (en) 2005-03-30 2018-06-19 Primal Fusion Inc. Knowledge representation systems and methods incorporating inference rules
AU2006290870B2 (en) 2005-09-14 2013-02-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
DK1986679T3 (da) 2006-02-22 2017-11-20 Mannkind Corp Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
CN103252007B (zh) 2008-06-13 2016-06-22 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI792140B (zh) * 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
RU2531455C2 (ru) * 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
US10474647B2 (en) 2010-06-22 2019-11-12 Primal Fusion Inc. Methods and devices for customizing knowledge representation systems
CN105667994B (zh) 2011-04-01 2018-04-06 曼金德公司 用于药物药盒的泡罩包装
CN105106200A (zh) * 2011-05-17 2015-12-02 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
CA2835927A1 (en) * 2011-05-17 2012-11-22 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
WO2013063160A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
ES2814336T3 (es) * 2012-04-13 2021-03-26 Glaxosmithkline Ip Dev Ltd Partículas de agregado
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
CN102872027B (zh) * 2012-09-18 2014-03-12 刘晓忠 一种治疗肺部疾病的药物颗粒的制备和吸入式复方气雾剂的制备
EP2948148B1 (en) * 2013-01-28 2020-07-29 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
GB201301721D0 (en) * 2013-01-31 2013-03-20 Prosonix Ltd Pharmaceutical Preparations
EP2950792A1 (en) 2013-01-31 2015-12-09 Prosonix Limited Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
CA2901015A1 (en) * 2013-03-04 2014-09-12 Besins Healthcare Luxembourg Sarl Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
CA2898700C (en) * 2013-03-14 2022-07-19 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
SG11201509543YA (en) * 2013-05-22 2015-12-30 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of three or more active agents
CN105451716A (zh) 2013-07-18 2016-03-30 曼金德公司 热稳定性干粉药物组合物和方法
US20160243320A1 (en) * 2013-10-07 2016-08-25 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhaler
CA2930170A1 (en) * 2013-11-22 2015-05-28 Teva Branded Pharmaceutical Products R&D, Inc. An inhalable medicament
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
CN104188941B (zh) * 2014-09-02 2016-11-16 重庆和平制药有限公司 一种制备盐酸克仑特罗吸入粉雾剂的方法
CA2961660A1 (en) * 2014-10-01 2016-04-07 Als Mountain Llc Pharmaceutical composition comprising aspirin, metformin, and serotonin with non-ionic surfactant
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
WO2017108917A1 (en) 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
WO2017157265A1 (zh) * 2016-03-15 2017-09-21 广东东阳光药业有限公司 喷雾剂、喷雾装置以及喷雾组件
WO2017201003A1 (en) * 2016-05-17 2017-11-23 Mayo Foundation For Medical Education And Research Materials and methods for treating chronic cough
KR102559152B1 (ko) 2016-06-30 2023-07-26 필립모리스 프로덕츠 에스.에이. 니코틴 입자
PE20191043A1 (es) * 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
JP6906947B2 (ja) * 2016-12-22 2021-07-21 キヤノン株式会社 画像処理装置、撮像装置、画像処理方法およびコンピュータのプログラム
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
CN107243080B (zh) * 2017-06-21 2021-11-12 上海上药信谊药厂有限公司 一种吸入式气雾剂、其原料组合物及制备方法
IL273713B2 (en) * 2017-10-09 2023-10-01 Pearl Therapeutics Inc Drug delivery systems and related methods
JP7372727B2 (ja) 2017-11-20 2023-11-01 三菱重工業株式会社 系統運用者側コンピュータ、発電事業者側コンピュータ、電力システム、制御方法及びプログラム
EP3860580A4 (en) * 2018-10-01 2022-07-20 Kindeva Drug Delivery L.P. FORMULATION AND AEROSOL CARTRIDGES, INHALATORS AND THE LIKE CONTAINING THE FORMULATION
CN112789033A (zh) * 2018-10-02 2021-05-11 学校法人名城大学 吸入粉末剂、其评价方法及其用途
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法
WO2020229966A1 (en) * 2019-05-10 2020-11-19 Glenmark Pharmaceutical Limited Stable aerosol composition for inhalation comprising glycopyrronium
CN112137957B (zh) 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN112804991B (zh) * 2019-06-27 2022-03-11 广州谷森制药有限公司 含富马酸福莫特罗和阿地溴铵的可吸入溶液制剂
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
JP2023513969A (ja) * 2020-02-20 2023-04-04 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 緩衝化医薬製剤を含む加圧定量吸入器
AU2021276611A1 (en) * 2020-05-18 2022-12-15 Orexo Ab New pharmaceutical composition for drug delivery
US20220000767A1 (en) * 2020-07-06 2022-01-06 Sensory Cloud, Inc. Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi
WO2022016068A1 (en) * 2020-07-16 2022-01-20 Tbd Pharma Llc Dexamethasone solution for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections
US11844793B2 (en) 2020-09-29 2023-12-19 Aerorx Therapeutics Llc Liquid formulations of indacaterol
CN116710104A (zh) * 2021-01-08 2023-09-05 江苏恒瑞医药股份有限公司 可通过定量吸入器递送的药物组合物
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
IL309888A (en) 2021-07-09 2024-03-01 Astrazeneca Pharmaceuticals Lp Aerosol drug delivery compounds, methods and systems
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
JP2024541470A (ja) 2021-11-25 2024-11-08 オレクソ・アクチエボラゲット アドレナリンを含む医薬組成物
EP4452230A1 (en) 2021-12-20 2024-10-30 Astrazeneca AB Compositions, methods and systems for aerosol drug delivery
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法
WO2023212191A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Combination of albuterol and budesonide for the treatment of asthma
WO2024206662A1 (en) * 2023-03-30 2024-10-03 Aerorx Therapeutics Llc Liquid formulations of indacaterol and glycopyrronium
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用
US20250268914A1 (en) * 2024-02-26 2025-08-28 Honeywell International Inc. Fluticasone delivery compositions, devices and methods
CN118787617A (zh) * 2024-09-14 2024-10-18 苏州易合医药有限公司 一种吸入粉剂及其制备方法

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (enExample) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) * 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
CA1201114A (en) * 1980-02-15 1986-02-25 Gordon H. Phillipps Androstane carbothioates
DE3260474D1 (en) 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
FR2651678B1 (fr) 1989-09-08 1992-04-30 Glaxo Group Ltd Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone.
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
PL165803B1 (pl) 1990-09-10 1995-02-28 Schering Corp Sposób wytwarzania nowego monohydratu 9a, 21-dichloro-16-a metylo-1,4-pregnadieno-11 ß , 17a-diolo-3,20-diono-17-(2’furanokarboksylanu) PL PL PL PL
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
US5635563A (en) 1991-04-01 1997-06-03 Tomoegawa Paper Co., Ltd. Polyaniline derivatives and their production process
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
WO1993011773A1 (en) 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5849263A (en) 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
WO1995015151A1 (en) 1993-12-02 1995-06-08 Abbott Laboratories Aerosol drug formulations for use with non-cfc propellants
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
JPH09508695A (ja) 1994-02-09 1997-09-02 キナートン・リミテッド 溶液から材料を乾燥する方法
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
DE69530325T2 (de) * 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
DE19614421C2 (de) 1996-04-12 1999-12-16 Biovision Gmbh Verfahren zur Herstellung eines biodegradierbaren Knochenersatz- und Implantatwerkstoffes und biodegradierbarer Knochenersatz- und Implantatwerkstoff
GB9610821D0 (en) 1996-05-23 1996-07-31 Glaxo Wellcome Inc Metering apparatus
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
DE59709927D1 (de) * 1996-11-11 2003-05-28 Noe Christian Verwendung eines pharmazeutisch geeigneten Salzes von (3R,2'R)-3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium zur Herstellung eines Arzneimittels
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
ATE284677T1 (de) 1997-03-20 2005-01-15 Schering Corp Herstellung von pulveragglomeraten
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
DE69814428T2 (de) * 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
HUP0101733A3 (en) 1998-03-05 2001-12-28 Senju Pharma Co Pharmaceutical compositions containing sulfonyl-dipeptides and their use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6260549B1 (en) * 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ATE283033T1 (de) 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
DK1131059T3 (da) * 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
GB9912639D0 (en) * 1999-05-28 1999-07-28 Britannia Pharmaceuticals Ltd Improvements in and relating to treatment of respiratory conditions
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
NZ512383A (en) 1998-12-22 2003-05-30 Univ North Carolina Use of osmotic agents in the treatment of airway diseases and for the delivery of airway drugs
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
EP1158958B1 (en) 1999-03-05 2007-06-06 CHIESI FARMACEUTICI S.p.A. Improved powdery pharmaceutical compositions for inhalation
SE9900833D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DK1169019T3 (da) 1999-04-14 2003-06-02 Glaxo Group Ltd Farmaceutisk aerosolformulering
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
TW453876B (en) 1999-06-30 2001-09-11 Inhale Therapeutic Syst Spray drying process control of drying kinetics
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
NZ500555A (en) 1999-08-02 2000-11-24 Hovione Int Ltd Process for the preparation of mometasone furoate
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
CN1188111C (zh) * 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
DE19961300A1 (de) 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US20030026766A1 (en) 2000-04-13 2003-02-06 Mark Sanders Medicaments for treating respiratory disorders comprising formoterol and fluticasone
CA2382133C (en) * 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
AU2000265583A1 (en) 2000-08-15 2002-02-25 Carsten Berg Quaternary ammonium salts of 1,2-benzisothiazolin-3-one. preparation and use as biocides
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
DK2283818T3 (en) * 2000-11-30 2017-10-16 Vectura Ltd Process for preparing particles for use in a pharmaceutical composition
DK1337240T4 (en) 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
EP1345629A2 (en) 2000-12-29 2003-09-24 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
US20040197271A1 (en) * 2001-03-20 2004-10-07 Kunka Robert Leonard Inhalation drug combinations
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
WO2002078761A1 (fr) * 2001-03-30 2002-10-10 Laboratoires Genevrier Neo-tissu cartilagineux greffable
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
DE10202940A1 (de) * 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10214264A1 (de) 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen eines Anhydrats
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
KR20060011783A (ko) * 2002-06-12 2006-02-03 에피제네시스 파마슈티칼스 아이엔씨 데하이드로에피안드로스테론 스테로이드 및항-무스카린제와 더불어 호흡기 및 폐 질환을 치료하기위한 조성물, 제제 및 키트
DE10237739A1 (de) 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
JP2005536538A (ja) 2002-08-23 2005-12-02 シェーリング　コーポレイション 薬学的組成物
CN1694689A (zh) 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US6942821B2 (en) * 2002-10-15 2005-09-13 Cryovac, Inc. Process for triggering, storing, and distributing an oxygen scavenger, and a stored oxygen scavenger
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
DE10323966A1 (de) 2003-05-27 2004-12-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
MXPA05012821A (es) 2003-05-28 2006-02-13 Nektar Therapeutics Formulacion farmaceutica que comprende un agente activo insoluble en agua.
US7238664B2 (en) * 2003-06-16 2007-07-03 Altana Pharma Ag Composition comprising a pulmonary surfactant and a PDE5 inhibitor for the treatment of lung diseases
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
CA2533791C (en) 2003-07-28 2012-05-22 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising betamimetics and an anticholinergic agent
RU2361586C2 (ru) 2003-07-29 2009-07-20 Берингер Ингельхайм Интернациональ Гмбх Комбинация из антихолинергического средства и стероида и ее применение для лечения заболеваний дыхательных путей путем ингаляции
PT1651270E (pt) 2003-07-29 2007-04-30 Boehringer Ingelheim Int Medicamentos para inalação compreendendo betamiméticos e um anticolinérgico
CA2534120C (en) 2003-07-31 2012-09-11 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
EP1925293A3 (en) 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
JP2007517069A (ja) * 2003-12-31 2007-06-28 サイデックス・インコーポレイテッド スルホアルキルエーテルγ−シクロデキストリンおよびコルチコステロイドを含む吸入製剤
PT1713473E (pt) * 2004-02-06 2013-05-13 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd
DE602005007708D1 (de) 2004-02-06 2008-08-07 Meda Pharma Gmbh & Co Kg Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
WO2005077339A1 (en) 2004-02-10 2005-08-25 E.I. Dupont De Nemours And Company Process for preparing stable sol of pharmaceutical ingredients and hydrofluorocarbon comprising milling the said sol, then transfert it into a canister
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PL1765288T3 (pl) 2004-06-18 2013-04-30 Novartis Ag Preparaty tobramycyny do leczenia zakażań oskrzeli
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
US20060140873A1 (en) 2004-12-27 2006-06-29 Chang Heng W Aerosol pharmaceutical compositions
JP2008534480A (ja) 2005-03-24 2008-08-28 ソーセイ アールアンドディ リミテッド グリコピロニウム塩およびそれらの治療的使用
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
WO2006114379A1 (de) 2005-04-23 2006-11-02 Boehringer Ingelheim International Gmbh Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP1893203A2 (en) 2005-05-31 2008-03-05 Boehringer Ingelheim International GmbH Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
CA2611907A1 (en) 2005-06-17 2006-12-21 Boehringer Ingelheim International Gmbh Mrp iv inhibitors for the treatment of respiratory diseases
AU2006272438B2 (en) 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
EP1906919A4 (en) 2005-07-15 2012-12-26 Map Pharmaceuticals Inc MULTIPLE ACTIVE PHARMACEUTICAL PRINCIPLES COMBINED IN DISCRETE INHALATION PARTICLES AND THEIR FORMULATIONS
CN100560598C (zh) * 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
AT502396B1 (de) 2005-09-01 2007-03-15 Montanuniv Leoben Verfahren zum abtrennen von verunreinigungen aus einsatzstoffen
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
NZ568349A (en) * 2005-12-21 2011-05-27 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
EP1981475A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Pharmaceutical formulations
JP2009537585A (ja) 2006-05-24 2009-10-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療のための新規医薬組成物
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0614621D0 (en) * 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
JP2010519195A (ja) * 2007-02-19 2010-06-03 シプラ・リミテッド 薬学的組成物
EP1964564A1 (en) * 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
EP2036572A1 (en) 2007-09-04 2009-03-18 Novo Nordisk A/S Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle
CN101317821B (zh) * 2007-11-15 2012-01-04 陈晓东 适用于肺部给药的超细干粉颗粒及其制备方法
PT2234595E (pt) * 2007-12-13 2013-01-24 Novartis Ag Processo para redução da tendência de um sal de glicopirrónio para se agregar durante a armazenagem
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
FR2940162B1 (fr) 2008-12-22 2011-02-25 Boehm & Cie Ets Outil de frappe multi-usages a mecanisme absorbant l'energie transmise au moyen de prehension
WO2010097188A1 (en) 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI792140B (zh) * 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
BR112012024059B1 (pt) 2010-04-01 2021-06-01 Chiesi Farmaceutici S.P.A. Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco
EP2627317A4 (en) 2010-10-15 2014-08-20 Glaxo Group Ltd MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE
RU2013142268A (ru) 2011-02-17 2015-03-27 Сипла Лимитед Фармацевтическая композиция
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
CA2835927A1 (en) 2011-05-17 2012-11-22 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
SG11201509543YA (en) 2013-05-22 2015-12-30 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of three or more active agents

Also Published As

Publication number Publication date
US20250009652A1 (en) 2025-01-09
LUC00124I1 (enExample) 2019-06-13
AU2010253770B2 (en) 2014-12-11
US20190038548A1 (en) 2019-02-07
HUE047803T2 (hu) 2020-05-28
LT3106149T (lt) 2020-03-10
KR20120034631A (ko) 2012-04-12
LTC2435025I2 (lt) 2021-02-10
BRPI1011229A2 (pt) 2016-03-15
EP2435025B1 (en) 2016-07-06
MX393243B (es) 2025-03-24
JP5873012B2 (ja) 2016-03-01
BRPI1011229B8 (pt) 2021-05-25
FR19C1040I1 (enExample) 2020-07-31
IL216466B (en) 2018-08-30
JP2015199735A (ja) 2015-11-12
BRPI1011229B1 (pt) 2020-10-13
SI2435024T1 (sl) 2016-10-28
KR101926060B1 (ko) 2018-12-06
TWI695723B (zh) 2020-06-11
RU2580315C2 (ru) 2016-04-10
LT3111927T (lt) 2020-03-25
MX350164B (es) 2017-08-29
KR20120026075A (ko) 2012-03-16
NO2021019I1 (no) 2021-05-12
JP6169639B2 (ja) 2017-07-26
EP2435023B1 (en) 2016-07-06
TWI792140B (zh) 2023-02-11
DK3111926T3 (da) 2020-03-02
SI3111927T1 (sl) 2020-08-31
HK1169307A1 (zh) 2013-01-25
TW201936174A (zh) 2019-09-16
TW201700123A (zh) 2017-01-01
MX2011012783A (es) 2012-06-28
ES2774367T3 (es) 2020-07-20
ME03631B (me) 2020-07-20
LUC00124I2 (enExample) 2019-12-27
US20150017247A1 (en) 2015-01-15
WO2010138862A3 (en) 2011-04-14
AR076806A1 (es) 2011-07-06
KR101748892B1 (ko) 2017-06-19
LT2435024T (lt) 2016-09-26
ES2589135T3 (es) 2016-11-10
US20210186861A1 (en) 2021-06-24
EP3111926B1 (en) 2019-12-11
MX2011012684A (es) 2012-05-23
US20180125776A1 (en) 2018-05-10
BRPI1011220A2 (pt) 2016-03-15
AU2010253950B2 (en) 2014-12-04
BRPI1011220B1 (pt) 2020-03-10
ZA201108275B (en) 2023-04-26
HRP20200166T1 (hr) 2020-05-15
US20170071850A1 (en) 2017-03-16
TWI546094B (zh) 2016-08-21
SMT202000077T1 (it) 2020-03-13
PL3106149T3 (pl) 2020-06-01
CY2019031I2 (el) 2019-11-27
WO2010138868A3 (en) 2011-04-28
ES2774391T3 (es) 2020-07-20
PT3111926T (pt) 2020-02-28
CY1118040T1 (el) 2017-05-17
RU2713404C2 (ru) 2020-02-05
AR076807A1 (es) 2011-07-06
TW201109049A (en) 2011-03-16
EP3111926A1 (en) 2017-01-04
KR20180130602A (ko) 2018-12-07
RU2586297C2 (ru) 2016-06-10
CN105193773B (zh) 2018-12-11
US8808713B2 (en) 2014-08-19
CN105193773A (zh) 2015-12-30
CN102753152A (zh) 2012-10-24
JP2012528792A (ja) 2012-11-15
US20110135737A1 (en) 2011-06-09
HUS2100018I1 (hu) 2021-06-28
JP2017222706A (ja) 2017-12-21
CA2763941A1 (en) 2010-12-02
SI2435025T1 (sl) 2016-10-28
CN107669664B (zh) 2020-07-10
PH12017500778A1 (en) 2018-01-22
EP3111927A1 (en) 2017-01-04
PL2435023T3 (pl) 2017-06-30
PT2435024T (pt) 2016-10-13
SMT202000108T1 (it) 2020-03-13
US10716753B2 (en) 2020-07-21
TW201642836A (zh) 2016-12-16
HUE031229T2 (en) 2017-06-28
LUC00208I2 (enExample) 2022-10-07
NL300995I1 (enExample) 2019-06-24
WO2010138868A2 (en) 2010-12-02
HRP20161098T1 (hr) 2016-10-21
EP3106149A1 (en) 2016-12-21
HUE029532T2 (en) 2017-03-28
KR20190049943A (ko) 2019-05-09
RU2016107464A3 (enExample) 2019-08-19
HRP20200298T1 (hr) 2020-06-12
HK1169027A1 (zh) 2013-01-18
WO2010138862A2 (en) 2010-12-02
FR19C1040I2 (fr) 2020-07-31
CY2021012I1 (el) 2021-10-15
IL216467A0 (en) 2012-01-31
JP6189356B2 (ja) 2017-08-30
KR101976107B1 (ko) 2019-05-09
SI2435023T1 (sl) 2016-10-28
SMT201600326B (it) 2016-11-10
JP6876734B2 (ja) 2021-05-26
HRP20161102T1 (hr) 2016-11-04
US20110023876A1 (en) 2011-02-03
RU2011154148A (ru) 2013-07-10
TWI633898B (zh) 2018-09-01
JP2015187108A (ja) 2015-10-29
JP6492124B2 (ja) 2019-03-27
BRPI1011508A2 (pt) 2016-03-22
CA2763936C (en) 2017-10-03
SMT201600329B (it) 2016-11-10
HUE031283T2 (hu) 2017-07-28
RU2016117972A3 (enExample) 2019-09-27
CY2021012I2 (el) 2021-10-15
CY1122749T1 (el) 2021-03-12
TWI632926B (zh) 2018-08-21
DK2435023T3 (en) 2016-10-24
MX350163B (es) 2017-08-29
EP3106149B1 (en) 2019-11-20
CA2763939A1 (en) 2010-12-02
JP2016041713A (ja) 2016-03-31
AU2010253770A1 (en) 2011-11-24
RU2011154083A (ru) 2013-07-10
AU2010253950A1 (en) 2011-12-08
SMT202000109T1 (it) 2020-03-13
WO2010138884A3 (en) 2011-04-21
WO2010138884A2 (en) 2010-12-02
RU2580315C3 (ru) 2021-06-18
MX337126B (es) 2016-02-12
RU2751771C2 (ru) 2021-07-16
HK1244669A1 (zh) 2018-08-17
CY1118030T1 (el) 2017-05-17
EP2435025A2 (en) 2012-04-04
TW201919730A (zh) 2019-06-01
RU2016107464A (ru) 2018-11-22
US20110132357A1 (en) 2011-06-09
AU2010253776B2 (en) 2015-01-22
TWI717511B (zh) 2021-02-01
JP2018008942A (ja) 2018-01-18
HK1218867A1 (zh) 2017-03-17
NO2019026I1 (no) 2019-06-13
JP2018048150A (ja) 2018-03-29
PL3111927T3 (pl) 2020-06-29
LT3111926T (lt) 2020-03-25
CN107669664A (zh) 2018-02-09
HUE047834T2 (hu) 2020-05-28
TW201109051A (en) 2011-03-16
PT3106149T (pt) 2020-02-19
CA2763936A1 (en) 2010-12-02
CN107412212A (zh) 2017-12-01
CY1122732T1 (el) 2021-03-12
DK3111927T3 (da) 2020-03-09
MX2011012685A (es) 2012-06-12
TWI539979B (zh) 2016-07-01
EP2435024B1 (en) 2016-07-06
IL216468B (en) 2018-12-31
DK3106149T3 (da) 2020-02-24
AU2010253776A1 (en) 2011-11-24
LTC2435024I2 (enExample) 2022-06-27
MX377778B (es) 2025-03-11
ES2593429T3 (es) 2016-12-09
LT2435025T (lt) 2016-09-26
LTPA2021511I1 (enExample) 2021-06-25
IL216466A0 (en) 2012-01-31
JP5873013B2 (ja) 2016-03-01
JP2019108369A (ja) 2019-07-04
KR20170070274A (ko) 2017-06-21
PL3111926T3 (pl) 2020-06-29
JP2012528199A (ja) 2012-11-12
TW201109050A (en) 2011-03-16
DK2435025T3 (en) 2016-10-24
EP2435024A2 (en) 2012-04-04
HK1169026A1 (zh) 2013-01-18
JP5823383B2 (ja) 2015-11-25
JP2012528200A (ja) 2012-11-12
CN107412212B (zh) 2021-01-22
IL216467B (en) 2018-12-31
RU2016117972A (ru) 2018-10-29
CY1122807T1 (el) 2021-05-05
EP3111927B1 (en) 2019-12-11
CN102596176B (zh) 2017-09-19
JP6348645B2 (ja) 2018-06-27
PT3111927T (pt) 2020-03-03
US20190307676A1 (en) 2019-10-10
PL2435024T3 (pl) 2017-01-31
ES2772253T3 (es) 2020-07-07
PL2435025T3 (pl) 2017-08-31
DK2435024T3 (en) 2016-10-24
CN102458364A (zh) 2012-05-16
PT2435025T (pt) 2016-11-11
ZA201208102B (en) 2013-09-25
RU2020102859A (ru) 2021-07-26
RU2015151358A3 (enExample) 2019-07-29
SMT201600327B (it) 2016-11-10
AU2010253770B9 (en) 2015-02-12
MX2020004077A (es) 2020-07-29
EP2435023A2 (en) 2012-04-04
HRP20200260T1 (hr) 2020-05-29
CN102458364B (zh) 2016-11-02
CY1118034T1 (el) 2017-05-17
HUE047823T2 (hu) 2020-05-28
CN102596176A (zh) 2012-07-18
IL216468A0 (en) 2012-01-31
ZA201208101B (en) 2013-07-31
HK1247095A1 (zh) 2018-09-21
ZA201208100B (en) 2013-07-31
LT2435023T (lt) 2016-09-26
RU2011152960A (ru) 2013-07-10
TWI707700B (zh) 2020-10-21
US20170112759A1 (en) 2017-04-27
TWI646980B (zh) 2019-01-11
AU2010253950C1 (en) 2015-09-17
PT2435023T (pt) 2016-10-14
RU2015151358A (ru) 2019-01-16
AR076621A1 (es) 2011-06-22
CN102753152B (zh) 2015-09-23
KR20170104003A (ko) 2017-09-13
US9463161B2 (en) 2016-10-11
HRP20161101T1 (hr) 2016-11-04
NL300995I2 (nl) 2019-10-29
ES2592536T3 (es) 2016-11-30
SI3111926T1 (sl) 2020-07-31
KR20120015334A (ko) 2012-02-21
CY2019031I1 (el) 2019-11-27
HUS1900031I1 (hu) 2019-07-29
TW202114642A (zh) 2021-04-16
LTPA2019014I1 (lt) 2019-07-10
TW201808372A (zh) 2018-03-16
US20110132356A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
SI3106149T1 (sl) Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi
PL3335707T3 (pl) Kombinacje antagonisty receptora muskarynowego i agonisty receptora beta-2 adrenergicznego
PT2627649E (pt) Antagonistas do receptor cxcr4
ZA201101120B (en) Compositions of pd-1 antagonists and methods of use
IL232477A (en) Cyclohexylamine derivatives with the activity of beta 2-adrenergic agonist and 3m muscarinic antagonist
ZA201207031B (en) New cyclohexylamine derivatives having b2 adrenergic agonist and m3 muscarinic antagonist activities
ZA201105323B (en) Agonists and antagonists of the sip5 receptor,and methods of uses thereof
SI2552920T1 (sl) Nove nk-3 receptor selektivne antagonist spojine, farmacevtski sestavki in postopki za uporabo pri nk-3 receptor posredovanih motnjah
ZA201100866B (en) Tripyridyl carboxamide orexin receptor antagonists
IL214501A0 (en) Histamine h3 inverse agonists and antagonists and methods of use thereof
PL2598526T3 (pl) Agoniści i antagoniści receptora typu i chimerycznej interleukiny il-1
ZA201107743B (en) Diamide compounds having muscarinic receptor antagonist and b2 adrenergic receptor agonist activity
SG10201506076TA (en) Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
IL216802A0 (en) Histamine h3 inverse agonists and antagonists and methods of use thereof
EP2262371A4 (en) LPA RECEPTOR AGONISTS AND ANTAGONISTS
HUE037394T2 (hu) Clever-1 receptor antagonisták immun-gátló 2 típusú makrofágok blokkolására
HUE038366T2 (hu) Módszer szabályozó T-sejtek alfa-2B adrenerg receptor agonistákkal való aktiválásához
IL237150B (en) Preparations containing combinations of receptor antagonists and agonists
IL218037A0 (en) New benzimidazole derivatives and their use as fxr agonists
EP2657225A4 (en) SUBSTITUTED METHYL AMINES, 5-HT6 SEROTONIN RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING
HK1185270A (en) Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
DOP2009000013A (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
ZA201107552B (en) Composition of pd-1 antagonists and methods of use
ZA201105874B (en) Histamine h3 inverse agonists and antagonists and methods of use thereof